Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 19/20 | 0.60 |
| ▸ | PPARA | Q07869 | 10/20 | 0.60 |
| ▸ | PPARG | P37231 | 8/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2521255 | 0.86 | PPARA (0.59) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL2527202 | 0.84 | PPARD (0.55) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL6498825 | 0.78 | PPARD (0.59) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL6487110 | 0.76 | PPARD (0.57) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL5656255 | 0.75 | PPARD (1.00) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL5656300 | 0.74 | PPARD (0.81) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL6236634 | 0.74 | PPARD (1.00) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL6129288 | 0.74 | PPARD (0.83) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL5656612 | 0.73 | PPARD (0.75) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL5655979 | 0.73 | PPARD (0.89) | PPARDPPARAPPARGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048658-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-02-25 | — | — | US | claimed |
| US-8039500-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20100048658-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048658-A1 | FUSED HETEROCYCLIC COMPOUNDS | CRHR1, CRHR2, CRH | PPARD 1892/4885PPARA 2523/4885PPARG 2525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.